Combination of two anti‐CD5 monoclonal antibodies synergistically induces complement‐dependent cytotoxicity of chronic lymphocytic leukaemia cells

Summary The treatment of chronic lymphocytic leukaemia (CLL) has been improved by introduction of monoclonal antibodies (mAbs) that exert their effect through secondary effector mechanisms. CLL cells are characterized by expression of CD5 and CD23 along with CD19 and CD20, hence anti‐CD5 Abs that en...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2013-10, Vol.163 (2), p.182-193
Hauptverfasser:	Klitgaard, Josephine L., Koefoed, Klaus, Geisler, Christian, Gadeberg, Ole V., Frank, David A., Petersen, Jørgen, Jurlander, Jesper, Pedersen, Mikkel W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Alemtuzumab Antibodies, Monoclonal - immunology Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized - pharmacology antibody combinations Antibody-Dependent Cell Cytotoxicity - drug effects Antibody-Dependent Cell Cytotoxicity - immunology Antibody-dependent cell-mediated cytotoxicity Antigens, CD20 - immunology Antigens, CD20 - metabolism Biological and medical sciences CD5 CD5 Antigens - immunology CD5 Antigens - metabolism Cell Line, Tumor Cell Survival - drug effects Chromosome Aberrations chronic lymphocytic leukaemia Complement System Proteins - immunology complement‐dependent cytotoxicity Cytotoxicity, Immunologic - drug effects Drug Synergism epitope binning Female Hematologic and hematopoietic diseases Humans Leukemia, Lymphocytic, Chronic, B-Cell - genetics Leukemia, Lymphocytic, Chronic, B-Cell - immunology Leukemia, Lymphocytic, Chronic, B-Cell - metabolism Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!